

SPECTRUM PHARMACEUTICALS INC  
Form 8-K  
December 05, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 2, 2008**

**SPECTRUM PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation)

**000-28782**

(Commission File Number)

**93-0979187**

(IRS Employer Identification No.)

**157 Technology Drive, Irvine, California**

(Address of Principal Executive Offices)

**92618**

(Zip Code)

Registrant's telephone number, including area code: **(949) 788-6700**

**Not Applicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On December 2, 2008, Spectrum Pharmaceuticals, Inc. reported, during its investor conference call, that sales of its proprietary oncology product, Fusilev<sup>®</sup>, have exceeded \$2 million to date.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**December 5, 2008**

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Shyam Kumaria  
Name: Shyam Kumaria  
Title: V.P. Finance